Skip to main content
. 2020 Apr 21;11:291. doi: 10.3389/fneur.2020.00291

Table 1.

General demographic, clinical and neuropsychological characteristics of participant groups.

Characteristics Controls bvFTD SD PNFA LPA AD
General demographic and clinical
No. (M/F) 32 (16/16) 34 (26/8) 17 (10/7) 20 (10/10) 9 (8/1) 28 (13/15)
Age (y) 68.2 (6.9) 65.8 (6.9) 66.5 (7.5) 68.5 (8.4) 69.2 (9.6) 70.4 (7.8)
Handedness (R/L) 29/2 32/1 17/0 18/1 8/1 25/2
Education (y) 16.1 (2.4) 13.8 (4.0) 15.0 (2.9) 13.6 (2.5) 16.2 (2.1) 14.9 (2.0)
MMSE (/30) 29.8 (0.4) 22.4 (6.4) 21.8 (8.0) 18.4 (9.5) 13.1 (7.8) 18.1 (6.6)
Symptom dur (y) N/A 7.2 (5.0) 6.1 (2.4) 4.3 (2.4) 5.2 (1.9) 6.9 (3.6)
Medication use**: no (%) 2 (0.6) 16 (47) 6 (35) 8 (40) 2 (22) 13 (46)
Neuropsychological
General intellect
WASI VIQ 123.7 (8.2)a 82.4 (27.6)c 67.9 (18.3)a 72.3 (18.9)b 61.3 (19.1) 93.1 (20.2)a
WASI PIQ 125.2 (12.9)a 92.8 (22.9)c 114.5 (17.5)a 88.8 (22.4)b 81.7 (12.9) 82.6 (16.7)a
Episodic memory
RMT Words (/50) 48.8 (1.2)a 28.4 (18.8)g 26.3 (16.3)d 31.1 (18.4)b 20.2 (20.3) 25.4 (11.5)e
RMT Words (/25)* 24.7 (0.8) N/A N/A N/A N/A 15.3 (3.5)
RMT Faces (/50) 43.9 (5.0)a 23.7 (15.8)f 26.9 (11.7)b 30.5 (15.8)b 19.9 (19.7) 26.7 (11.7)e
RMT Faces (/25)* 24.6 (0.7) N/A N/A N/A N/A 17.8 (2.8)
Executive function
DS-F (max) 7.2 (1.1)a 5.7 (1.4)a 6.6 (0.9)a 3.8 (2.2)c 3.0 (2.4) 5.9 (1.4)a
DS-R (max) 5.5 (1.3)a 3.6 (1.8)a 5.0 (1.5)a 1.9 (1.6)c 1.8 (1.4) 3.3 (1.8)b
D-KEFS Stroop:
Color (s) 30.1 (4.9)b 53.8 (22.0)a 52.6 (23.2)a 77.3 (19.8)d 81.9 (13.7) 57.4 (17.1)d
Word (s) 23.3 (5.0)b 35.5 (19.0)a 32.0 (18.4)a 70.3 (25.5)d 60.8 (22.8) 44.4 (22.5)d
Interference (s) 54.8 (13.2)b 119.9 (54.8)a 96.9 (45.9)a 155.9 (44.8)d 180.0 (0.0) 145.6 (40.5)d
Fluency:
Verbal (total) 17.7 (5.7)a 6.6 (5.4)a 6.9 (5.4)a 4.1 (4.4)d 2.0 (2.9) 8.9 (4.9)b
Category (total) 24.6 (5.4)a 10.0 (6.9)a 5.3 (4.4)a 9.4 (7.2)d 2.2 (2.9) 8.0 (5.0)a
TMT A (s) 31.1 (9.2)a 75.7 (46.4)a 53.5 (27.7)a 82.1 (45.4)d 116.9 (37.6) 99.3 (42.4)a
TMT B (s) 60.2 (24.1)a 202.2 (93.5)a 147.3 (88.4)a 229.2 (94.4)c 300.0 (0.0) 269.7 (69.0)c
Language skills
BPVS (/150) 148.0 (1.4)a 110.7 (45.5)e 62.1 (39.8)b 117.6 (44.4)b 92.6 (55.0) 124.1 (36.7)a
GNT (/30) 26.6 (2.7)a 12.1 (9.3)d 1.0 (4.0)a 10.7 (7.2)c 7.0 (8.5)a 12.5 (8.3)b
Other skills
VOSP (/20) 18.9 (1.2)a 14.2 (5.2)d 14.1 (4.7)a 15.1 (4.7)b 13.6 (3.7) 15.4 (2.6)a

Mean (standard deviation) values are shown unless otherwise indicated (maximum scores on neuropsychological tests are in parentheses); significant differences in performance between healthy controls and patient groups (p < 0.05) are coded in bold.

*

based on data from an historical cohort of 24 healthy older controls and six patients with AD from the present cohort;

**

includes medications with a potentially relevant effect on time perception (see text).

A reduced number of participants completed certain tests, as follows:

a

n-1,

b

n-2,

c

n-3,

d

n-4,

e

n-7,

f

n-9,

g

n-11.

AD, patient group with typical Alzheimer's disease; BPVS, British Picture Vocabulary Scale (67); bvFTD, patient group with behavioral variant frontotemporal dementia; Controls, healthy control group; D-KEFS, Delis Kaplan Executive System (68); dur, duration; F, female; GDA, Graded Difficulty Arithmetic test (69); GNT, Graded Naming Test (70); LPA, patient group with logopenic aphasia; M, male; MMSE, Mini-Mental State Examination score (71); N/A, not applicable; PIQ, performance IQ; PNFA, patient group with progressive non-fluent aphasia; RMT, Recognition Memory Test (72); SD, patient group with semantic dementia; TMT, Trails Making Test (73); VIQ, verbal IQ; VOSP, Visual Object and Space Perception Battery – Object Decision test (74); WASI, Wechsler Abbreviated Scale of Intelligence (75); DS-F/R, Wechsler Memory Scale (Revised) Digit Span – Forward/Reverse (76); y, years.